NGM BIOPHARMACEUTICALS INC
DelistedCIK 1426332fmd_0X6VH9P1K9FXJRARFXT9M81KBQManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2017 to Dec 31, 2023, 25 periods
| Line item | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 |
|---|---|---|---|---|---|---|---|
| Total revenues | 77 | 109 | 104 | 87 | 78 | 55 | 4 |
| Research and development | 80 | 96 | 129 | 164 | 162 | 181 | 118 |
| Total operating expenses | 95 | 113 | 153 | 191 | 199 | 222 | 156 |
| Operating income | (17) | (4) | (49) | (104) | (121) | (166) | (151) |
| Other non-operating income (expense) | (0) | 0 | (0) | (1) | (0) | (0) | (0) |
| Income before taxes | (15) | (0) | (43) | (102) | (120) | (163) | (142) |
| Income tax expense | (1) | 0 | 0 | – | – | – | – |
| Net income from continuing operations | (14) | (0) | (43) | – | – | – | – |
| Net income | (14) | (0) | (43) | (102) | (120) | (163) | (142) |